English

Lazuriton Nano Biotechnology (U.S.A.) Inc.

EDGAR

Quarterly report (10-Q) · filed 2023-07-05

26 filing records in this dataset, filed from 2016-03-11 to 2023-07-05. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2022 Q1 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

0 USD

2022 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: 0 USD Source

Cash and cash equivalents: 1.35 thousand USD 2021-06-30 Source
Exact value

1348 USD
Long-term debt including current maturities: Not available
Shares outstanding: 100 million shares 2022-03-31 Source
Exact value

100000000 shares

Reported share-count change

0.00% · 0 shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

100000000 shares · 2021-03-31· Source
100000000 shares · 2022-03-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2021-04-01 – 2022-03-31

Exact inputs and evidence

Revenue: 0 USD · 2021-04-01 – 2021-06-30 Source
Revenue: 0 USD · 2021-07-01 – 2021-09-30 Source
Revenue: 0 USD · 2021-01-01 – 2021-12-31 Source
Revenue: 0 USD · 2021-01-01 – 2021-09-30 Source
Revenue: 0 USD · 2022-01-01 – 2022-03-31 Source

Net income

-48.8 thousand USD

2021-04-01 – 2022-03-31

Exact inputs and evidence

Net income: -9950 USD · 2021-04-01 – 2021-06-30 Source
Net income: -9950 USD · 2021-07-01 – 2021-09-30 Source
Net income: -48800 USD · 2021-01-01 – 2021-12-31 Source
Net income: -30850 USD · 2021-01-01 – 2021-09-30 Source
Net income: -10950 USD · 2022-01-01 – 2022-03-31 Source

Operating cash flow

0 USD

2021-04-01 – 2022-03-31

Exact inputs and evidence

Operating cash flow: 0 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: 0 USD · 2021-01-01 – 2021-03-31 Source
Operating cash flow: 0 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: 0 USD · 2021-01-01 – 2021-06-30 Source
Operating cash flow: 0 USD · 2021-01-01 – 2021-12-31 Source
Operating cash flow: 0 USD · 2021-01-01 – 2021-09-30 Source
Operating cash flow: 0 USD · 2022-01-01 – 2022-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-07-05.

Financial data available through: 2021-12-31.

Financial coverage is incomplete. Newer filings are recorded, but comparable financial figures for those periods are not available here yet.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2021-12-31
Operating income: 6 of 11 periods available· newest 2021-12-31
Net income: 6 of 11 periods available· newest 2021-12-31
Operating cash flow: 6 of 11 periods available· newest 2021-12-31
capital expenditure: No compatible figures in this window
Total assets: 5 of 11 periods available· newest 2021-12-31
Total liabilities: 5 of 11 periods available· newest 2021-12-31
Current assets: 5 of 11 periods available· newest 2021-12-31
Current liabilities: 5 of 11 periods available· newest 2021-12-31
Cash and cash equivalents: 4 of 11 periods available· newest 2020-12-31
long term debt: No compatible figures in this window
Shares outstanding: 5 of 11 periods available· newest 2021-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
USD 0

Prior period

USD 0

2020-01-01 – 2020-12-31
Current period

USD 0

2021-01-01 – 2021-12-31

Exact inputs and evidence

0 − 0 = 0 USD

0 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
0 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2021-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Year-over-year change in Revenue: 0 USD Concept: fundies:Revenue Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#331834 Filing: 000164033423000748 Input fundies:Revenue: 0 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#332388 Filing: 000164033423000748
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 2,441

Prior period

−USD 51,241

2020-01-01 – 2020-12-31
Current period

−USD 48,800

2021-01-01 – 2021-12-31

Exact inputs and evidence

-48800 − -51241 = 2441 USD

-51241 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
-48800 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2021-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Year-over-year change in Net income: 2441 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -48800 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#412211 Filing: 000164033423000748 Input fundies:NetIncome: -51241 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#412406 Filing: 000164033423000748
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-100%

Prior period

USD 1

2020-01-01 – 2020-12-31
Current period

USD 0

2021-01-01 – 2021-12-31

Exact inputs and evidence

0 − 1 = -1 USD

1 USD · 2020-01-01 – 2020-12-31
Inspect prior input Prior source
0 USD · 2021-01-01 – 2021-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2021-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Year-over-year change in Operating cash flow: -1 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#367788 Filing: 000164033423000748 Input fundies:OperatingCashFlow: 1 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#368498 Filing: 000164033423000748
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Capital expenditure.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2021 2021-01-01 – 2021-12-31

Revenue USD 0
Operating costs Derived USD 48,800
Operating income −USD 48,800
Tax, interest and other Derived USD 0
Net income −USD 48,800

Cash

Operating cash flow USD 0
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2019 Not shown: operating income or net income is not reported.
2020 Not shown: operating income or net income is not reported.
2021 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2016 2016-01-01 – 2016-12-31	58382 Derived	-58382	-15 Derived	-58367	Unavailable	Source 2016-01-01 – 2016-12-31: 0 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -58382 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -58367 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 90737 USD Inspect Operating Cash Flow Open source
2017 2017-01-01 – 2017-12-31	175864 Derived	-175864	-8 Derived	-175856	Unavailable	Source 2017-01-01 – 2017-12-31: 0 USD Inspect Revenue Open source 2017-01-01 – 2017-12-31: -175864 USD Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -175856 USD Inspect Net Income Open source 2017-01-01 – 2017-12-31: -299735 USD Inspect Operating Cash Flow Open source
2019 2019-01-01 – 2019-12-31	71775 Derived	-71775	0 Derived	-71775	Unavailable	Source 2019-01-01 – 2019-12-31: 0 USD Inspect Revenue Open source 2019-01-01 – 2019-12-31: -71775 USD Inspect Operating Income Open source 2019-01-01 – 2019-12-31: -71775 USD Inspect Net Income Open source 2019-01-01 – 2019-12-31: 150 USD Inspect Operating Cash Flow Open source
2020 2020-01-01 – 2020-12-31	51242 Derived	-51242	-1 Derived	-51241	Unavailable	Source 2020-01-01 – 2020-12-31: 0 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -51242 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -51241 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 1 USD Inspect Operating Cash Flow Open source
2021 2021-01-01 – 2021-12-31	48800 Derived	-48800	0 Derived	-48800	Unavailable	Source 2021-01-01 – 2021-12-31: 0 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -48800 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -48800 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: 0 USD Inspect Operating Cash Flow Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2021

Values and sources

Revenue values and source evidence
Period	Series	Source evidence
20162016-12-31	Revenue	Revenue: 0 Open source
20172017-12-31	Revenue	Revenue: 0 Open source
20192019-12-31	Revenue	Revenue: 0 Open source
20202020-12-31	Revenue	Revenue: 0 Open source
20212021-12-31	Revenue	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20172017-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20192019-12-31	Year over year	No prior comparable period	Revenue: 0 Open source
20202020-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source
20212021-12-31	Year over year	No prior comparable period	Revenue: 0 Open source Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Operating margin	Not reported	Operating Income: -58382 Open source Revenue: 0 Open source
20172017-12-31	Operating margin	Not reported	Operating Income: -175864 Open source Revenue: 0 Open source
20192019-12-31	Operating margin	Not reported	Operating Income: -71775 Open source Revenue: 0 Open source
20202020-12-31	Operating margin	Not reported	Operating Income: -51242 Open source Revenue: 0 Open source
20212021-12-31	Operating margin	Not reported	Operating Income: -48800 Open source Revenue: 0 Open source
20162016-12-31	Net margin	Not reported	Net Income: -58367 Open source Revenue: 0 Open source
20172017-12-31	Net margin	Not reported	Net Income: -175856 Open source Revenue: 0 Open source
20192019-12-31	Net margin	Not reported	Net Income: -71775 Open source Revenue: 0 Open source
20202020-12-31	Net margin	Not reported	Net Income: -51241 Open source Revenue: 0 Open source
20212021-12-31	Net margin	Not reported	Net Income: -48800 Open source Revenue: 0 Open source
20162016-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: 90737 Open source
20172017-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -299735 Open source
20192019-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: 150 Open source
20202020-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: 1 Open source
20212021-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: 0 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 0 2021

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Operating cash flow	90737	Operating Cash Flow: 90737 Open source
20172017-12-31	Operating cash flow	-299735	Operating Cash Flow: -299735 Open source
20192019-12-31	Operating cash flow	150	Operating Cash Flow: 150 Open source
20202020-12-31	Operating cash flow	1	Operating Cash Flow: 1 Open source
20212021-12-31	Operating cash flow	0	Operating Cash Flow: 0 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20162016-12-31	Free cash flow	Unavailable	Operating Cash Flow: 90737 Open source
20172017-12-31	Free cash flow	Unavailable	Operating Cash Flow: -299735 Open source
20192019-12-31	Free cash flow	Unavailable	Operating Cash Flow: 150 Open source
20202020-12-31	Free cash flow	Unavailable	Operating Cash Flow: 1 Open source
20212021-12-31	Free cash flow	Unavailable	Operating Cash Flow: 0 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

27,442.5% 2021

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Liabilities / assets	227.2%	Total Liabilities: 229311 Open source Total Assets: 100928 Open source
20172017-12-31	Liabilities / assets	8,837.6%	Total Liabilities: 105432 Open source Total Assets: 1193 Open source
20192019-12-31	Liabilities / assets	20,035.9%	Total Liabilities: 269883 Open source Total Assets: 1347 Open source
20202020-12-31	Liabilities / assets	23,822.3%	Total Liabilities: 321125 Open source Total Assets: 1348 Open source
20212021-12-31	Liabilities / assets	27,442.5%	Total Liabilities: 369925 Open source Total Assets: 1348 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0× 2021

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20162016-12-31	Current assets / current liabilities	0.44×	Current Assets: 100928 Open source Current Liabilities: 229311 Open source
20172017-12-31	Current assets / current liabilities	0.01×	Current Assets: 1193 Open source Current Liabilities: 105432 Open source
20192019-12-31	Current assets / current liabilities	0×	Current Assets: 1347 Open source Current Liabilities: 269883 Open source
20202020-12-31	Current assets / current liabilities	0×	Current Assets: 1348 Open source Current Liabilities: 321125 Open source
20212021-12-31	Current assets / current liabilities	0×	Current Assets: 1348 Open source Current Liabilities: 369925 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2016 2016-01-01 – 2016-12-31	−USD 58,367 Exact value Exact value: -58367 USD 2016-01-01 – 2016-12-31: -58367 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2016-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Net Income: -58367 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -58367 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033418000622/lnbi-20171231.xml#25059 Filing: 000164033418000622 The citation records this snapshot. The page link may show a newer release later.	USD 90,737 Exact value Exact value: 90737 USD 2016-01-01 – 2016-12-31: 90737 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2016-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Operating Cash Flow: 90737 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 90737 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033418000622/lnbi-20171231.xml#27456 Filing: 000164033418000622 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2017 2017-01-01 – 2017-12-31	−USD 175,856 Exact value Exact value: -175856 USD 2017-01-01 – 2017-12-31: -175856 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2017-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Net Income: -175856 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -175856 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033419001147/lnbi-20181231.xml#24964 Filing: 000164033419001147 The citation records this snapshot. The page link may show a newer release later.	−USD 299,735 Exact value Exact value: -299735 USD 2017-01-01 – 2017-12-31: -299735 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2017-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Operating Cash Flow: -299735 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -299735 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033419001147/lnbi-20181231.xml#27547 Filing: 000164033419001147 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2018 2018-01-01 – 2018-12-31	−USD 92,522 Exact value Exact value: -92522 USD 2018-01-01 – 2018-12-31: -92522 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2018-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Net Income: -92522 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -92522 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033421001627/lnbi-20191231.xml#20950 Filing: 000164033421001627 The citation records this snapshot. The page link may show a newer release later.	USD 4 Exact value Exact value: 4 USD 2018-01-01 – 2018-12-31: 4 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2018-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Operating Cash Flow: 4 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033421001627/lnbi-20191231.xml#23027 Filing: 000164033421001627 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2019 2019-01-01 – 2019-12-31	−USD 71,775 Exact value Exact value: -71775 USD 2019-01-01 – 2019-12-31: -71775 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2019-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Net Income: -71775 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -71775 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033421002291/lznn_10k.htm#226235 Filing: 000164033421002291 The citation records this snapshot. The page link may show a newer release later.	USD 150 Exact value Exact value: 150 USD 2019-01-01 – 2019-12-31: 150 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2019-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Operating Cash Flow: 150 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 150 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033421002291/lznn_10k.htm#190520 Filing: 000164033421002291 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2020 2020-01-01 – 2020-12-31	−USD 51,241 Exact value Exact value: -51241 USD 2020-01-01 – 2020-12-31: -51241 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2020-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Net Income: -51241 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51241 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#412406 Filing: 000164033423000748 The citation records this snapshot. The page link may show a newer release later.	USD 1 Exact value Exact value: 1 USD 2020-01-01 – 2020-12-31: 1 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2020-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Operating Cash Flow: 1 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#368498 Filing: 000164033423000748 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.
2021 2021-01-01 – 2021-12-31	−USD 48,800 Exact value Exact value: -48800 USD 2021-01-01 – 2021-12-31: -48800 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2021-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Net Income: -48800 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -48800 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#412211 Filing: 000164033423000748 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2021-01-01 – 2021-12-31: 0 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lazuriton Nano Biotechnology (U.S.A.) Inc. · 2021-12-31 Lazuriton Nano Biotechnology (U.S.A.) Inc. (edgar:1666178) Operating Cash Flow: 0 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T14:09:24Z Snapshot: db30924fed081f562a120c3916afece590398436fec25afe5415c575251023a1 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1666178/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 0 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1666178/000164033423000748/lznn_10k.htm#367788 Filing: 000164033423000748 The citation records this snapshot. The page link may show a newer release later.	Unavailable Not reported for this period.	Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

26 filings · 886 latest values · 886 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001666178, 1666178, edgar:1666178, lnbi

Also known as Lazuriton Nano Biotechnology (U.S.A.) Inc, Lazuriton Nano Biotechnology (U.S.A.) Inc.

Lazuriton Nano Biotechnology (U.S.A.) Inc.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Where revenue goes

2021 2021-01-01 – 2021-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation